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THE PROBLEM
Malfunction of the lower esophageal
sphincter results in acid reflux into the
esophagus. Reflux is mostly episodic so
that the esophagus is not often presented
with a continuous acid load. Prediction of
esophageal disease related to reflux takes
into account the pH of the refluxate and
the duration of reflux. Expulsion of the
refluxate back into the stomach shortens
the time ofexposure. The volume ofreflux
is also an important parameter for estima-
tion of the acid load on the esophageal
epithelium. It is the magnitude ofthis acid
load that determines the presence or
absence of pathology or symptoms. Intra-
esophageal pH monitoring provides an
approximate measure of the acid load to
the lower esophagus [2, 3]
The human esophageal epithelium is a
multi-layered, stratified squamous epithe-
lium. Afferent nerves are present, reaching
into the superficial layers of the mucosa.
With incompetence of the lower
esophageal sphincter (LES)b, acid reflux
results with pain anddamage to the epithe-
lium depending on the pH ofthe refluxate.
Rather than being protected by a continu-
ous tight junction, this epithelium has
largely regional cell-to-cell contact via
desmosomes but, being multi-layered, pro-
vides a winding path for proton diffusion
into the epithelium. It is nevertheless sig-
nificantly more acid sensitive than the gas-
tric epithelium that is provided with
"tight" tightjunctions.
The threshold of acidity for damage
and pain may be different. A higher acidi-
ty is likely needed for damage to the
epithelial cells compared to the acidity
required for stimulation of the pain fibers.
This is probably because the epithelial
cells have acidrecovery mechanisms (such
as Na/H or anion exchange) mostly absent
in the pain fibers. Dependent on the loca-
tion ofthe pain fibers and the access there-
to of H+, different individuals will have
different sensitivities to luminal acidity.
These thoughts raise the question as to the
therapeutic aims of acid control, elevation
ofmean diurnal pH forhealing oferosions
or prevention of acidic excursions for
symptom relief or both.
aTo whom allcorrespondence shouldbe addressed:George Sachs, UCLA and Wadsworth
VA, Los Angeles, CA 90073.
bAbbreviations: LES, lower esophageal sphincter; PPI, proton pump inhibitor.
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ESOPHAGEAL HANDLING OF
ACID
Given the absence ofcontinuous tight
junctions, the lower esophageal epitheli-
um is an inviting target for acid back dif-
fusion. Mucus is an aqueous gel and is
unlikely to provide a significant barrier to
acid back diffusion.
Resistance to acid may, therefore,
depend more on the ability of the
esophageal epithelium to neutralize an
acid load than on restriction of entry of
acid. Neutralization of acid will occur at
the surface due to netHC03- secretion and
in the paracellular pathway since the
epithelial cells can produce the buffer or
absorb HW. However, once damage has
occurred, the paracellular pathway is
shorter or more open and the lesion conse-
quently more sensitive to acid than the
normal epithelium.
The measured average net flux of
bicarbonate is about 78 ,umol/30 min/10
cm in the human esophagus [1]. It appears
to be subject to regulation by muscarinic
receptors, responding to the vagal stimula-
tion of acid secretion by the stomach. It is
possible to approximate the pH of
unbuffered refluxate that can be neutral-
ized by esophageal surface secretion. If
buffering is present, such as that due to
amino acids or weak acids such as citrate,
the acid load will be greater in the buffer-
ing range of gastric contents and not
reflect only pH.
With reflux orunbuffered gastric con-
tents at a pH of4.0, there is a load ofacid
equivalent to 100 nmollml. If 10 ml of
gastric contents at thatpH is refluxed each
min for 30 min and spreads over a length
of 10 cm, 30 pmol of acid is presented to
the esophagus. This is within the average
neutralizing ability ofthe secreted HC03-
Reflux at pH 4.0 should, therefore, be
largely neutralized at or close to the
esophageal surface.
At pH of 3.0, there is 10-fold more
acid, and 300 pmol of acid is presented to
the lower esophagus, with 10 ml refluxing
each min. This is beyond the capacity of
net HC03- secretion to neutralize the HCl.
Acidification of intercellular spaces is
likely, which may result in pain in some
individuals. Epithelial cell pH may remain
within viable limits give adequate Na/H or
C1-/HCO3- exchange.
ESOPHAGEAL HANDLING OF
PEPSIN
Gastric contents contain pepsin in
addition to acid. Proteolytic activity of
pepsin:requires a pH below 3.0, and prob-
ably there is adequate neutralization of
intercellular pH if the refluxate does not
fall much below 3.0. At a refluxate of pH
2.0, since the esophageal surface cannot
neutralize this acid load, peptic activity
may begin to contribute to esophageal
damage. Peptic activity is less likely to
contribute directly to pain.
RATIONALE FORTREATMENT
Treatment of reflux esophagitis can
be accomplished by improving the
response or structure of the LES or by
effective inhibition of acid secretion.
Currently available compounds targeted to
the LES are relatively nonselective com-
pounds and have lower efficacy than acid
inhibition. Ideally, control of GERD, in
terms ofboth healing and symptom relief,
would not allow gastric pH to fall much
below 4.0 at any time.
The most effective means of control
of intragastric pH is the use of PPIs. PPIs
only inhibit active gastric acid pumps, and
only about 80 percent of the pumps are
active during the plasma dwell time (60 to
90 min) ofthe drugs that are given 30 min
afterbreakfast. The half-life ofrecovery of
the pumps is about 24 hr, due primarily to
de novo biosynthesis ofthepump(t1/2 = 50
hr [4]) and perhaps also to reversal of the
disulfide bond linking PPI to thepump. On
once-a-day treatment, the inhibition of
maximal acid output is about 70 percent
[5]. Steady-state inhibition is found on
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ment dosing since previously resting
pumps have to be recruited to respond to
the drug. Improvement in effect of PPIs is
achieved by divided doses, not by increas-
ing the single dose. On twice-a-day treat-
ment, inhibition of maximal acid output
rises to 80 percent and steady-state is
achieved on day two.
Meta-analysis of the degree of acid
inhibition required for optimization of
healing rates for erosive esophagitis that
has shown that elevation of mean diurnal
intra-gastric pH to at least 4.0 is required
forabout 18 hrperday [6]. This result may
reflect the calculated ability of the epithe-
lium and its cells to handle acid reflux.
This seems to be achieved in most patients
on once-a-day PPI therapy. If eradication
of Helicobacterpylori blunts the effect of
PPIs on intragastric acidity, as has recent-
ly been suggested [7], twice-a-day PPI
therapy may be required to reach optimal
healing pH.
Thus, inhibition to pH below 4.0 is
sufficient to optimize healing but is often
inadequate for complete symptom control,
since intra-gastric acidity may increase to
pH below 2.0, especially towards the end
of digestion of a meal. Short periods of
high acidity, which may not result in
epithelial damage, may be sufficient to
stimulate esophageal nerves, and the meta-
analysis only addresses diurnal pH, not
periods ofhigh acidity.
Rapid symptom control may require
more frequent dosing for the first three
days until steady-state inhibition is
reached or reformulation of the PPIs.
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